| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6190137 | Bulletin du Cancer | 2015 | 12 Pages |
Abstract
Myelodysplastic syndromes are heterogeneous diseases whose molecular characteristics have only been identified in recent years. Better identification of prognostic factors, larger access to allogeneic stem cell transplantation and the advent of new drugs notably hypomethylating agents (azacitidine, decitabine) and lenalidomide have improved patient outcome.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Matthieu Duchmann, Pierre Fenaux, Thomas Cluzeau,